etoposide has been researched along with Neuroendocrine Tumors in 42 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (7.14) | 18.2507 |
| 2000's | 7 (16.67) | 29.6817 |
| 2010's | 20 (47.62) | 24.3611 |
| 2020's | 12 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Feng, ST; Li, Z; Luo, Y; Shi, S; Song, C; Wang, Y | 1 |
| Mansoor, Q; Ng, J; Sadiq, M | 1 |
| Albers, D; Kasper, S; Lahner, H; Markus, P; Mende, B; Mika, S; Reis, H; Rosery, V; Schmid, KW; Schuler, M; Schumacher, B; Siveke, JT; Stuschke, M; Treckmann, J; Wiesweg, M | 1 |
| Adamo, V; Cantale, O; Castorina, L; Chillari, F; Colarossi, C; Esposito, F; Franchina, T; Giuffrida, D; Puliafito, I; Ricciardi, GRR; Russo, A; Sciacca, D; Vitale, MP | 1 |
| Gu, X; Guan, Y; Hao, Y; Song, Z; Sun, Y; Wang, W; Xiang, J; Yao, Q; Zeng, X | 1 |
| Bhosale, P; Chisholm, GB; Flores Legarreta, A; Frumovitz, M; Gonzales, NR; Jhingran, A; Ramalingam, P; Saab, R; Salvo, G | 1 |
| Aye, J; Beierle, EA; Clay, MR; Coleman, A; Hoppmann, A; Mroczek-Musulman, E; Ranganathan, S; Tynes, C; Whelan, KF; Williams, AP; Williams, GR | 1 |
| Han, Y; Li, L; Sun, H | 1 |
| Halfdanarson, TR; Leventakos, K; Molina, JR; Uprety, D | 1 |
| Afchain, P; Baudin, E; Desgrippes, R; Hadoux, J; Hautefeuille, V; Lepage, C; Lorgis, V; Monterymard, C; Scoazec, JY; Thuillier, F; Tougeron, D; Walter, T | 1 |
| Alonso-Gordoa, T; Brabander, T; Cadiot, G; Caminoa, A; Capdevila, J; Chakrabarty, B; Couvelard, A; Cros, J; de Mestier, L; García Gómez-Muriel, MI; Garcia-Alvarez, A; Hernando, J; Kats-Ugurlu, G; Lamarca, A; Landolfi, S; Manoharan, P; Pavel, ME; Perrier, M; Ronot, M; Van Velthuysen, MF; Walenkamp, AM; Zandee, W | 1 |
| Akeno, N; Callahan, M; He, D; Kim, RG; Lane, A; Miller, AL; Moulton, JS; Reece, AL; Wikenheiser-Brokamp, KA | 1 |
| Erdelkamp, R; Hentrich, M; Stief, C; Tritschler, S | 1 |
| Balasubramaniam, S; Bates, SE; Bonner, WM; Bryla, C; Figg, WD; Fojo, T; Giaccone, G; Lee, MJ; Peer, CJ; Piekarz, RL; Rajan, A; Redon, CE; Tomita, Y; Trepel, JB | 1 |
| Ali, AS; Grönberg, M; Grønbæk, H; Hjortland, GO; Janson, ET; Knigge, U; Ladekarl, M; Langer, SW; Österlund, P; Sorbye, H; Vestermark, LW; Welin, S | 1 |
| Hamano, Y; Hyodo, I; Moriwaki, T; Sakashita, S; To, K; Watahiki, T; Yamada, T | 1 |
| Boudreaux, JP; Ramirez, RA; Thiagarajan, R; Thomas, KEH; Voros, BA; Woltering, EA | 1 |
| Barriuso, J; Fazio, N; Frizziero, M; Hubner, RA; Kordatou, Z; Lamarca, A; Manoharan, P; Mansoor, W; McNamara, MG; Nuttall, C; Spada, F; Valle, JW | 1 |
| Awad, W; Mashni, O; Qasem, K; Sara, AA | 1 |
| Chi, YH; Du, F; Jiang, WC; Song, Y; Sun, YK; Wang, JW; Yang, L; Zhou, AP | 1 |
| Stone, MS; Tschetter, AJ; VanBeek, MJ | 1 |
| Barriuso, J; Borbath, I; Chougnet, CN; Crespo, G; Heetfeld, M; O'Toole, D; Olsen, IH; Pavel, M; Rinke, A; Walter, T | 1 |
| Ahn, SI; Lee, KY; Park, KM; Park, SY; Shin, WY | 1 |
| Bhattacharjee, A; Chaturvedi, P; D'Cruz, A; Dhumal, S; Joshi, A; Kane, S; Noronha, V; Pai, P; Patil, VM; Prabhash, K; Sharma, V; Zanwar, S | 1 |
| Chang, DK; Cho, YB; Ha, SY; Hong, SN; Huh, JW; Kim, HC; Kim, ST; Kim, YH; Lee, J; Lee, WY; Park, YA; Park, YS; Yun, SH | 1 |
| Wolin, EM | 1 |
| Alrifai, D; Childs, A; Edeline, J; Gillmore, R; Kirkwood, A; Lamarca, A; Luong, TV; Mayer, A; Meyer, T; Nsiah-Sarbeng, P; Sarker, D; Thirlwell, C; Valle, JW; Watkins, J | 1 |
| Adamenko, O; Belfiori, G; Cardinali, L; Crippa, S; Doglioni, C; Falconi, M; Muffatti, F; Palucci, M; Partelli, S; Zamboni, G | 1 |
| Gress, TM; Rinke, A | 1 |
| Fakih, M; Patta, A | 1 |
| Couvelard, A; de Gramont, A; Faivre, S; Hammel, P; Neuzillet, C; Raymond, E; Serova, M; Tijeras-Raballand, A | 1 |
| Campitiello, M; Plastino, F; Treglia, G | 1 |
| Adams, J; Amrein, P; Ancukiewicz, M; Fitzek, MM; Joseph, M; Mcintyre, J; Rosenthal, S; Thornton, AF; Varvares, M | 1 |
| Fujimoto, N; Fujiwara, K; Hamazaki, S; Kiura, K; Kozuki, T; Mizobuchi, K; Shiomi, K; Tabata, M; Tanimoto, M; Ueoka, H | 1 |
| Dalal, BI; Kollmannsberger, C; McArthur, HL | 1 |
| Abbey-Toby, A; Aparicio, T; Bouarioua, N; Chosidow, D; Karila Cohen, P; Mathieu, N; Soulé, JC; Stefanescu, C | 1 |
| Julie, C; Lepère, C; Maindrault-Goebel, F; Mitry, E; Otmezguine, Y; Rakotomalala, S; Rougier, P; Vaillant, JN | 1 |
| Bloom, SR; Hammond, PJ | 1 |
| Cera, PJ; Cha, SS; Creagan, ET; Goldberg, RM; Jung, SH; Marschke, RF; Myers, JL; Schleusener, JT; Tazelaar, HD | 1 |
| Aparicio, T; Baudin, E; Ducreux, M; Duvillard, P; Elias, D; Lasser, P; Mitry, E; Rougier, P; Rufié, P; Sabourin, JC; Schlumberger, M | 1 |
| Mitry, E; Rougier, P | 1 |
| Droz, JP; Flechon, A; Lombard-Bohas, C | 1 |
8 review(s) available for etoposide and Neuroendocrine Tumors
| Article | Year |
|---|---|
Pulmonary Neuroendocrine Tumors: Adjuvant and Systemic Treatments.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Capecitabine; Carcinoid Tumor; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Everolimus; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Lymph Node Excision; Molecular Targeted Therapy; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pneumonectomy; Protein Kinase Inhibitors; Radiopharmaceuticals; Receptors, Somatostatin; Somatostatin; Temozolomide; Watchful Waiting | 2020 |
Current Treatment Options in Gastroenteropancreatic Neuroendocrine Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Neuroendocrine; Cisplatin; Clinical Trials as Topic; Etoposide; Humans; Intestinal Neoplasms; Irinotecan; Neuroendocrine Tumors; Pancreatic Neoplasms; Prognosis; Progression-Free Survival; Radiopharmaceuticals; Stomach Neoplasms | 2019 |
Advances in the Diagnosis and Management of Well-Differentiated and Intermediate-Differentiated Neuroendocrine Tumors of the Lung.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Carcinoma, Neuroendocrine; Cisplatin; Disease Management; Etoposide; Everolimus; Humans; Lung Neoplasms; Neuroendocrine Tumors; Octreotide; Peptides, Cyclic; Pneumonectomy; Small Cell Lung Carcinoma; Somatostatin | 2017 |
Management of neuroendocrine carcinomas of the pancreas (WHO G3): A tailored approach between proliferation and morphology.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Neuroendocrine; Cell Proliferation; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Humans; Ki-67 Antigen; Mitotic Index; Neoadjuvant Therapy; Neoplasm Staging; Neuroendocrine Tumors; Pancreatectomy; Pancreatic Neoplasms; Prognosis | 2016 |
Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Neuroendocrine; Cisplatin; Etoposide; Gastrointestinal Neoplasms; Humans; Irinotecan; Ki-67 Antigen; Neoplasm Grading; Neuroendocrine Tumors; Practice Guidelines as Topic; Prognosis; Treatment Outcome | 2017 |
Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Resistance, Neoplasm; Etoposide; Everolimus; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Medical Oncology; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2012 |
Chemotherapy in the treatment of neuroendocrine malignant tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Doxorubicin; Etoposide; Fluorouracil; Gastrointestinal Neoplasms; Humans; Neuroendocrine Tumors; Pancreatic Neoplasms; Streptozocin | 2000 |
[Chemotherapy of neuroendocrine tumors].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Doxorubicin; Embolization, Therapeutic; Etoposide; Humans; Neuroendocrine Tumors; Prognosis; Streptozocin; Survival Analysis | 2002 |
4 trial(s) available for etoposide and Neuroendocrine Tumors
| Article | Year |
|---|---|
FOLFIRINEC: a randomized phase II trial of mFOLFIRINOX vs platinum-etoposide for metastatic neuroendocrine carcinoma of gastroenteropancreatic or unknown origin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Neuroendocrine; Etoposide; Female; Fluorouracil; Humans; Intestinal Neoplasms; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Oxaliplatin; Pancreatic Neoplasms; Platinum Compounds; Progression-Free Survival; Prospective Studies; Quality of Life; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2021 |
Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Glucuronosyltransferase; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neuroendocrine Tumors; Small Cell Lung Carcinoma; Sulfonamides; Treatment Outcome | 2018 |
Neuroendocrine differentiation is an independent prognostic factor in chemotherapy-treated nonsmall cell lung carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Cisplatin; Disease Progression; Etoposide; Female; Humans; Hydrazines; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neuroendocrine Tumors; Prognosis; Staining and Labeling | 1996 |
Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Differentiation; Cisplatin; Etoposide; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Survival Analysis | 1999 |
30 other study(ies) available for etoposide and Neuroendocrine Tumors
| Article | Year |
|---|---|
Optimization of the tumour response threshold in advanced gastroenteropancreatic neuroendocrine carcinomas treated with cisplatin/etoposide combined chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Cisplatin; Etoposide; Humans; Neuroendocrine Tumors; Treatment Outcome | 2022 |
Ocular toxicity following carboplatin chemotherapy for neuroendocrine tumour of the bladder.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Humans; Male; Neuroendocrine Tumors; Toxic Optic Neuropathy; Urinary Bladder; Vision Disorders | 2023 |
Identification of a new prognostic score for patients with high-grade metastatic GEP-NEN treated with palliative chemotherapy.
Topics: Etoposide; Gastrointestinal Neoplasms; Humans; Neuroendocrine Tumors; Pancreatic Neoplasms; Platinum; Prognosis; Retrospective Studies; Stomach Neoplasms | 2023 |
Therapeutic efficacy of platinum/etoposide regimens in the treatment of advanced poorly differentiated neuroendocrine carcinomas of the lung: A retrospective analysis.
Topics: Carboplatin; Carcinoma, Neuroendocrine; Cisplatin; Etoposide; Humans; Lung; Lung Neoplasms; Neuroendocrine Tumors; Platinum; Retrospective Studies | 2023 |
The combination of etoposide and platinum for the treatment of thymic neuroendocrine neoplasms: A retrospective analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Humans; Lung Neoplasms; Neuroendocrine Tumors; Platinum; Retrospective Studies | 2023 |
Clinicopathologic characteristics, oncologic outcomes, and prognostic factors in neuroendocrine cervical carcinoma: a Neuroendocrine Cervical Tumor Registry study.
Topics: Adult; Aged; Aged, 80 and over; Carboplatin; Carcinoma, Neuroendocrine; Cisplatin; Etoposide; Female; Humans; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Prognosis; Registries; Retrospective Studies; Uterine Cervical Neoplasms; Young Adult | 2023 |
Partial response to carboplatin, etoposide phosphate, and atezolizumab in a pediatric patient with high-grade metastatic tumor with rhabdoid and focal neuroendocrine features.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Etoposide; Humans; Liver Neoplasms; Male; Neoplasm Grading; Neuroendocrine Tumors; Organophosphorus Compounds; Rhabdoid Tumor; Treatment Outcome | 2020 |
Computed Tomography and Magnetic Resonance Imaging in the Diagnosis of Primary Neuroendocrine Tumors of the Liver.
Topics: Ablation Techniques; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Carcinoma, Neuroendocrine; Chemoembolization, Therapeutic; Cisplatin; Etoposide; Female; Hepatectomy; Humans; Liver Neoplasms; Lymph Nodes; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Grading; Neuroendocrine Tumors; Octreotide; Tomography, X-Ray Computed | 2020 |
Treatment outcomes of advanced digestive well-differentiated grade 3 NETs.
Topics: Adenocarcinoma; Etoposide; Humans; Neuroendocrine Tumors; Pancreatic Neoplasms; Platinum; Retrospective Studies; Somatostatin; Treatment Outcome | 2021 |
TRP53 Mutants Drive Neuroendocrine Lung Cancer Through Loss-of-Function Mechanisms with Gain-of-Function Effects on Chemotherapy Response.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred C57BL; Neuroendocrine Tumors; Sirolimus; Small Cell Lung Carcinoma; Tumor Suppressor Protein p53 | 2017 |
[Neuroendocrine prostate cancer].
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Chromogranin A; Cisplatin; Etoposide; Humans; Male; Neoplasms, Second Primary; Neuroendocrine Tumors; Phosphopyruvate Hydratase; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Survival Rate | 2017 |
Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Disease-Free Survival; Etoposide; Female; Humans; Infusions, Intravenous; Intestinal Neoplasms; Kaplan-Meier Estimate; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies; Stomach Neoplasms; Treatment Outcome | 2018 |
A Neuroendocrine Tumor of Unknown Primary Origin that Responded to Treatment Based on Tumor Grade Progression.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Neuroendocrine; Cisplatin; Etoposide; Hormones; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Somatostatin; Treatment Outcome | 2019 |
Carboplatin in Combination with Oral or Intravenous Etoposide for Extra-Pulmonary, Poorly-Differentiated Neuroendocrine Carcinomas.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Neuroendocrine; Cell Differentiation; Etoposide; Female; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Neuroendocrine Tumors; Retrospective Studies; Treatment Outcome; Young Adult | 2019 |
Etoposide dosage adjustment in two patients with neuroendocrine tumors and severe liver impairment.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Etoposide; Fatal Outcome; Female; Humans; Liver Neoplasms; Middle Aged; Neuroendocrine Tumors; Severity of Illness Index | 2020 |
[Neuroendocrine tumors: analysis of 252 cases].
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoid Tumor; Carcinoma, Merkel Cell; Carcinoma, Neuroendocrine; Cisplatin; Digestive System Neoplasms; Etoposide; Female; Fluorouracil; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Palliative Care; Retrospective Studies; Sex Factors; Survival Rate; Young Adult | 2013 |
A striking, localized eruption.
Topics: Antineoplastic Agents, Phytogenic; Drug Eruptions; Erythema; Etoposide; Humans; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms | 2014 |
Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Etoposide; Female; Fluorouracil; Humans; Ki-67 Antigen; Leucovorin; Male; Middle Aged; Neuroendocrine Tumors; Organoplatinum Compounds; Pancreatic Neoplasms; Prognosis; Survival Analysis; Young Adult | 2015 |
Cutaneous metastasis as an initial presentation of a non-functioning pancreatic neuroendocrine tumor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Gastrectomy; Humans; Lymphatic Metastasis; Male; Metastasectomy; Middle Aged; Neoplasm Recurrence, Local; Neuroendocrine Tumors; Pancreatectomy; Pancreatic Neoplasms; Reoperation; Skin Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Neoadjuvant Chemotherapy in Locally Advanced and Borderline Resectable Nonsquamous Sinonasal Tumors (Esthesioneuroblastoma and Sinonasal Tumor with Neuroendocrine Differentiation).
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Cisplatin; Cohort Studies; Disease-Free Survival; Esthesioneuroblastoma, Olfactory; Etoposide; Female; Follow-Up Studies; Humans; Male; Nasal Cavity; Nausea; Neoadjuvant Therapy; Neuroendocrine Tumors; Palliative Care; Paranasal Sinus Neoplasms; Survival Rate; Treatment Outcome | 2016 |
The Clinicopathologic Features and Treatment of 607 Hindgut Neuroendocrine Tumor (NET) Patients at a Single Institution.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Cisplatin; Colorectal Neoplasms; Disease-Free Survival; Endoscopy, Digestive System; Etoposide; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2016 |
Ki-67 index and response to chemotherapy in patients with neuroendocrine tumours.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Male; Middle Aged; Neoplasm Grading; Neuroendocrine Tumors; Platinum Compounds; Prognosis; Pyrimidines; Streptozocin; Young Adult | 2016 |
First-line cisplatin plus etoposide in high-grade metastatic neuroendocrine tumors of colon and rectum (MCRC NET): review of 8 cases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cisplatin; Colorectal Neoplasms; Demography; Disease-Free Survival; Etoposide; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Staging and treatment response evaluation in a metastatic neuroendocrine tumor of the pancreas with G2 grading: insights from multimodality diagnostic approach by F-18-FDG and Ga-68-DOTANOC PET/CT.
Topics: Cisplatin; Etoposide; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neuroendocrine Tumors; Pancreatic Neoplasms; Peptides, Cyclic; Radionuclide Imaging; Somatostatin; Treatment Outcome | 2013 |
Neuroendocrine tumors of the sinonasal tract. Results of a prospective study incorporating chemotherapy, surgery, and combined proton-photon radiotherapy.
Topics: Adult; Aged; Cisplatin; Combined Modality Therapy; Drug Therapy, Combination; Etoposide; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neuroendocrine Tumors; Nose Neoplasms; Otorhinolaryngologic Surgical Procedures; Paranasal Sinus Neoplasms; Prognosis; Prospective Studies; Radiotherapy, High-Energy; Salvage Therapy | 2002 |
Complexity in the treatment of pulmonary large cell neuroendocrine carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Large Cell; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neuroendocrine Tumors; Quinazolines; Radiotherapy, Adjuvant; Retrospective Studies; Treatment Failure; Treatment Outcome | 2005 |
Intravascular hemolysis as a complication of clostridium perfringens sepsis.
Topics: Anemia, Hemolytic; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Carcinoma, Small Cell; Cisplatin; Clostridium Infections; Clostridium perfringens; Etoposide; Hemolysis; Humans; Jaundice, Obstructive; Liver Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Systemic Inflammatory Response Syndrome | 2006 |
[How to treat well differentiated endocrine carcinoma with a high proliferative index? A case of gastric endocrine carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Humans; Male; Middle Aged; Neuroendocrine Tumors; Stomach Neoplasms | 2006 |
[Conservative treatment undifferentiated neuroendocrine tumors of the anal canal: two cases].
Topics: Adrenal Cortex Hormones; Aged; Anal Canal; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Biopsy; Brain Neoplasms; Cisplatin; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Male; Neuroendocrine Tumors; Radiotherapy Dosage; Remission Induction; Time Factors | 2007 |
Gut neuroendocrine tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Diazoxide; Etoposide; Fluorouracil; Gastrointestinal Neoplasms; Humans; Interferon-alpha; Neuroendocrine Tumors; Octreotide; Omeprazole; Pancreatic Neoplasms; Streptozocin | 1994 |